New drug cocktail targets Hard-to-Treat lung cancer mutation

NCT ID NCT05491811

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every three weeks. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ensartinib and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has a harder-to-treat genetic mutation.
What could go wrong: This is a small, early-phase trial with only 47 participants and no comparison group. The results may not apply to all patients, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.